{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:03Z","timestamp":1791644763706,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ophtha.2019.01.024","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T04:37:31Z","timestamp":1548650251000},"page":"792-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease"],"prefix":"10.1016","volume":"126","author":[{"given":"David L.","family":"Wirta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail L.","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-0937","authenticated-orcid":false,"given":"Helen R.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-7772","authenticated-orcid":false,"given":"John D.","family":"Lonsdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Ciolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrit","family":"Jentsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-2763","authenticated-orcid":false,"given":"George W.","family":"Ousler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kr\u00f6sser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2019.01.024_bib1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0161-6420(03)00462-7","article-title":"Utility assessment among patients with dry eye disease","volume":"110","author":"Schiffman","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.01.024_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ophtha.2019.01.024_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"CsA Phase 3 study group, two randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.01.024_bib4","first-page":"1","article-title":"Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomized, vehicle controlled phase III clinical studies","volume":"0","author":"Leonardi","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpb.2014.05.009","article-title":"Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery","volume":"88","author":"Dutescu","year":"2014","journal-title":"E\u00a0J Pham Biopharm"},{"key":"10.1016\/j.ophtha.2019.01.024_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","article-title":"Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs","volume":"538","author":"Agarwai","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ophtha.2019.01.024_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00417-016-3572-y","article-title":"A\u00a0semifluoronated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treament of dry eye","volume":"255","author":"Gehlsen","year":"2017","journal-title":"Graefes Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib8","first-page":"662","article-title":"Influence of aging on severity and anti-inflammatory treatment of experimental dry eye disease","volume":"234","author":"Steven","year":"2017","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.ophtha.2019.01.024_bib9","series-title":"Preferred Practice Pattern\u00ae Guidelines. Dry Eye Syndrome","year":"2013"},{"key":"10.1016\/j.ophtha.2019.01.024_bib10","first-page":"1458","article-title":"Flow cytometry in impression cytology specimens","volume":"38","author":"Baudouin","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.ophtha.2019.01.024_bib11","first-page":"1356","article-title":"Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes","volume":"41","author":"Brignole","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.01.024_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2125.1996.04231.x","article-title":"Estimating impossible curves using NONMEM","volume":"42","author":"Schoemaker","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1208\/ps020332","article-title":"Nonlinearity detection: advantages of nonlinear mixed-effects modeling","volume":"2","author":"Jonsson","year":"2000","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ophtha.2019.01.024_bib14","first-page":"410","article-title":"A\u00a0correlation between central corneal staining and visual function in patients diagnosed with dry eye","volume":"48","author":"Ousler","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.01.024_bib15","doi-asserted-by":"crossref","first-page":"9516","DOI":"10.1167\/iovs.11-8412","article-title":"Corneal fluorescein staining correlates with visual function in dry eye patients","volume":"52","author":"Kaido","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.01.024_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/ICO.0000000000000998","article-title":"Mechanisms of visual disturbance in dry eye","volume":"35","author":"Koh","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2019.01.024_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"Miljanovic","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0000000000000038","article-title":"A\u00a0review of quality of life measurements in dry eye questionnaires","volume":"33","author":"Grubbs","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2019.01.024_bib20","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease: a systematic review","volume":"9","author":"Bartlett","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib21","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1167\/iovs.03-0270","article-title":"The relationship between habitual patient-reported symptoms and clinical signs of among patients with dry eye of varying severity","volume":"44","author":"Begley","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.01.024_bib22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2019.01.024_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1542-0124(12)70187-8","article-title":"The association between symptoms of discomfort and signs in dry eye","volume":"7","author":"Johnson","year":"2009","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ophtha.2019.01.024_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/OPX.0b013e3182780dbb","article-title":"Evaluation of reading speed and contrast sensitivity in dry eye disease","volume":"90","author":"Ridder","year":"2013","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.ophtha.2019.01.024_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2015-308237","article-title":"Functional impairment of reading in patients with dry eye","volume":"101","author":"Mathews","year":"2017","journal-title":"Br J Ophthamol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A\u00a0randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.01.024_bib29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/OPTH.S101627","article-title":"The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye","volume":"10","author":"Stonecipher","year":"2016","journal-title":"Clin Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018321328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018321328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:06:29Z","timestamp":1758981989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018321328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0161642018321328"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.01.024","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}